comparemela.com

Page 4 - Ralph Kern News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update

/PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today.

United statesStanford schoolJohn mullalyKim thackerNetta blondheim shragaChaim lebovitsAntal pearl lendnerJonathan katzRalph kernSidney spectorLisa guitermanJames berryDrug administration for nurownStanford school of medicineCalifornia pacific medical centerResearch development

BrainStorm to Announce Second Quarter Results and Provide a Corporate Update

/PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today.

United statesJohn mullalyDavid setbounRalph kernChaim lebovitsStacy lindborgCalifornia institute for regenerative medicineBrainstorm cell therapeutics incLifesci advisorsDrug administrationPrnewswire brainstorm cell therapeutics incNational ms societyEuropean medicines agencyStorm cell therapeuticsChief executive officerChief medical officer

BrainStorm Announces Presentations at June 2022 Scientific Conferences

/PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces.

Stanford schoolUnited statesNational harborUnited kingdomCity ofSan franciscoJohn mullalyChaim lebovitsBrainstorm cell therapeutics incCalifornia institute for regenerative medicineLifesci advisorsStanford school of medicineCalifornia pacific medical centerDrug administrationEuropean network to cureConsortium of multiple sclerosis centers

Brainstorm Cell Therapeutics Inc s (BCLI) CEO Chaim Lebovits on Q1 2022 Results - Earnings Call Transcript

Brainstorm Cell Therapeutics Inc. (NASDAQ:NASDAQ:BCLI) Q1 2022 Earnings Conference Call May 16, 2022 8:00 A.M.

United statesKim thackerMichelle lorenzNetta blondheim shragaChaim lebovitsTom galassiBilly dunnDaniel walkerAntal pearl lendnerDavid setbounRalph kernAaron gertlerDavid bautzStacy lindborgCompany participantsBrainstorm cell therapeutics inc

BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update

/PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today.

United statesJohn mullalySeanm healeyKim thackerAntal pearl lendnerNetta blondheim shragaChaim lebovitsJames berryBrainstorm cell therapeutics incCalifornia institute for regenerative medicineLifesci advisorsDrug development summitInternational societyDrug administrationResearch developmentResearch summit on

vimarsana © 2020. All Rights Reserved.